AC Immune SA Stock News

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

AC Immune SA's Takeda Pharmaceutical Company partnership brought in an upfront payment of $100 million, with the potential to earn up to $2.1 billion in milestone payments. Interim safety and immunogenicity data from the phase 2 ABATE trial using ACI-24.060 for the treatment of Down Syndrome patients with AD, expected 2nd half of 2024. The global Alzheimer's therapeutics market size is expected...

AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease Treatment of first randomized person with preclinical AD expected this quarter Phase 2b ReTain trial is fully funded and conducted by development partner Lausanne, Switzerland, July 25, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for...

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, and prevention of neurodegenerative diseases, today announced that Company Management will participate in a fireside ...

AC Immune S.A. shares ACIU, -1.70% jumped more than 50% premarket on Monday after the Swiss biopharma company announced a licensing deal with Takeda Pharmaceutical Co. TAK, -0.90% for an experimental Alzheimer's disease vaccine.

AC Immune (NASDAQ: ACIU ) stock is heading higher on Monday alongside the clinical-stage biopharmaceutical company's earnings report for the first quarter of 2024. Included in that earnings report is an operational update that covers a new collaboration agreement with Takeda Pharmaceutical (NYSE: TAK ).

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billion ACI-24.060 ABATE Phase 2 trial on track to report Abeta-PET imaging results in Q2 2024, evaluating amyloid plaque reduction after 6 m...

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease